SCHEMBL2387474

SCHEMBL2387474

NC(=O)c1c(F)cccc1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.56
MRGPRX4 Q96LA9 2/20 0.56
KDM1A O60341 2/20 0.51
FOLH1 Q04609 1/20 0.51
HTT P42858 2/20 0.49
PARP1 P09874 1/20 0.49
PARP10 Q53GL7 1/20 0.49
PTGER1 P34995 2/20 0.48
MAPT P10636 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
HTR1A P08908 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
RXRA P19793 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5743109 0.89 FOLH1 (0.57) MRGPRX4FOLH1HTTPARP1PARP10
SCHEMBL2897224 0.88 MRGPRX4 (0.62) NPC1MRGPRX4KDM1AFOLH1PTGER1
SCHEMBL28964566 0.85 NPC1 (0.56) NPC1MRGPRX4KDM1AFOLH1PTGER1
SCHEMBL2892814 0.84 NPC1 (0.55) NPC1MRGPRX4KDM1AFOLH1HTT
SCHEMBL19285699 0.84 KDM1A (0.50) NPC1MRGPRX4KDM1AFOLH1HTT
SCHEMBL6358665 0.83 MAOB (0.56) MRGPRX4FOLH1HTTPARP1PARP10
SCHEMBL11464594 0.83 FOLH1 (0.52) MRGPRX4FOLH1HTTPARP1PARP10
SCHEMBL4599397 0.82 RXRA (0.60) NPC1MRGPRX4FOLH1HTTMAPT
SCHEMBL28964567 0.81 NPC1 (0.51) NPC1MRGPRX4KDM1AFOLH1PTGER1
SCHEMBL3032568 0.80 PLAU (0.51) NPC1MRGPRX4HTTPARP10PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0624567-B1 Derivatives of 3-fluorophenol, process for their preparation and their use CLARIANT GMBH (DE) 1999-12-08 EP claimed
EP-0624567-A2 Derivatives of 3-fluorophenol, process for their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1994-11-17 EP claimed
CN-115028680-B PROTAC compound for targeted degradation of Cyclophilin A and preparation method and application thereof 深圳湾实验室 2023-01-20 CN disclosed
CN-115028680-A PROTAC compound for targeted degradation of Cyclophilin A and preparation method and application thereof 深圳湾实验室 2022-09-09 CN disclosed
US-20110294749-A1 DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2011-12-01 US disclosed
EP-1518855-B1 DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE ASTELLAS PHARMA INC (JP) 2011-10-26 EP disclosed
US-8012959-B2 Diaminopyrimidinecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2011-09-06 US disclosed
CN-101880246-A Substituted benzoyl urea compound and preparation method and application thereof SHANGHAI INST MATERIA MEDICA 2010-11-10 CN disclosed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20090281072-A1 Diaminopyrimidinecarboxamide Derivative ASTELLAS PHARM INC. (JP) 2009-11-12 US disclosed
US-7449456-B2 Diaminopyrimidinecarboxamide derivative ASTELLAS PHARMA, INC. (JP) 2008-11-11 US disclosed
EP-1478629-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2004-11-24 EP disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-03-04 US disclosed
WO-2003072553-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed
EP-0624567-B1 Derivatives of 3-fluorophenol, process for their preparation and their use CLARIANT GMBH (DE) 1999-12-08 EP disclosed
EP-0628536-B1 Process for the preparation of aromatic amines CLARIANT GMBH (DE) 1999-07-14 EP disclosed
US-5410082-A Process for preparing amines CLARIANT GMBH (DE) 1995-04-25 US disclosed
EP-0628536-A2 Process for the preparation of amines HOECHST AKTIENGESELLSCHAFT (DE) 1994-12-14 EP disclosed
EP-0624567-A2 Derivatives of 3-fluorophenol, process for their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1994-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 NPC1 2741/4885MRGPRX4 4083/4885KDM1A 1528/4885
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 NPC1 2741/4885MRGPRX4 4083/4885KDM1A 1528/4885
US-20110294749-A1 DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE STAT6, STAT4, STAT3 NPC1 4203/4885MRGPRX4 1053/4885KDM1A 819/4885
US-20090281072-A1 Diaminopyrimidinecarboxamide Derivative STAT6, STAT4, STAT3 NPC1 4203/4885MRGPRX4 1053/4885KDM1A 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.